Document Type
Article Presentation
Original Publication Date
2024
Date of Submission
October 2024
Abstract
In order to protect against complications of Sickle Cell Disease, researchers used CRISPR-Cas9 gene editing to repeat CD34+ stem cells in an attempt to target and disrupt the HBG1 and HBG2 gene factors in sickle cell hemoglobin. Three participants were injected with OTQ923, the factored gene, and then monitored for F cell levels, hemoglobin levels, and fetal hemoglobin levels. Within 6-18 months, all 3 participants saw an increase in these factors from their original baseline.
Rights
© The Author(s)
